Overexpression of IRF2BP2 in the liver inhibits liver cancer induced by Hippo pathway inactivation.[42] IRF2BP2 was marked by an SE in AML samples, consistent with its high level of expression in AML.[43] Large‐scale CRISPR library screenings have shown that AML leukemia cells depend on IRF2BP2, and its disruption leads to an imbalance in inflammatory cytokine homeostasis, ultimately causing AML cell death. Here, IRF2BP2 is linked to liver cancer.